| 2025-08-14 |
详情>>
内部人交易：
PERKINS BRUCE D等共交易29笔
|
| 2025-07-30 |
详情>>
股本变动：
变动后总股本3288.67万股
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益2.71美元,归母净利润8909.60万美元,同比去年增长90.78%
|
| 2025-04-24 |
详情>>
业绩披露：
2025年一季报每股收益1.86美元,归母净利润6101.20万美元,同比去年增长323.69%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益3.65美元,归母净利润1.19亿美元,同比去年增长-43.27%
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益1.32美元,归母净利润4323.10万美元,同比去年增长543.53%
|
| 2024-12-10 |
股东大会：
将于2024-12-30召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2025 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2024.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益1.94美元,归母净利润6361.20万美元,同比去年增长318.83%
|
| 2024-07-25 |
详情>>
业绩披露：
2024年中报每股收益1.43美元,归母净利润4670.10万美元,同比去年增长184.87%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益0.44美元,归母净利润1440.00万美元,同比去年增长-42.96%
|
| 2024-04-25 |
详情>>
业绩披露：
2023年一季报每股收益0.78美元,归母净利润2524.60万美元,同比去年增长-20.29%
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-0.3美元,归母净利润-974.7万美元,同比去年增长-108.22%
|
| 2023-10-25 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.89美元,归母净利润-2906.9万美元,同比去年增长-133.45%
|
| 2023-08-10 |
股东大会：
将于2023-09-08召开股东大会
会议内容 ▼▲
- 1.To adopt the Merger Agreement, as it may be amended from time to time (the “Amedisys Merger Proposal”);
2.To approve, on a non-binding advisory basis, the compensation that may be paid or become payable to Amedisys named executive officers that is based on or otherwise relates to the transactions contemplated by the Merger Agreement (the “Amedisys Compensation Proposal”);
3.To approve the adjournment of the Amedisys Special Meeting, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the Amedisys Special Meeting to approve the Amedisys Merger Proposal (the “Amedisys Adjournment Proposal”).
|
| 2023-07-27 |
详情>>
业绩披露：
2023年中报每股收益-1.69美元,归母净利润-5502.9万美元,同比去年增长-189.84%
|
| 2023-06-05 |
复牌提示：
2023-06-05 07:00:12 停牌，复牌日期 2023-06-05 08:45:00
|
| 2023-05-03 |
财报披露：
美东时间 2023-05-03 盘后发布财报
|
| 2023-04-27 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2024 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
4.To approve, on an advisory (non-binding) basis, the frequency of future stockholder say on pay votes.
|
| 2022-04-27 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2023 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2022.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2021 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2020;
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2020-04-24 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2021 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2020;
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2019-04-26 |
股东大会：
将于2019-06-07召开股东大会
会议内容 ▼▲
- 1.To elect the seven director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2020 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2019.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2018-04-25 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2019 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2018.
3.To re-approve the material terms of the performance goals under the Amedisys, Inc. 2008 Omnibus Incentive Compensation Plan for Internal Revenue Code Section 162(m) purposes.
4.To approve the Amedisys, Inc. 2018 Omnibus Incentive Compensation Plan.
5.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
|
| 2017-04-25 |
股东大会：
将于2017-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2018 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2017.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say on pay” vote).
4.To approve, on an advisory (non-binding) basis, the frequency of future stockholder say on pay votes.
|
| 2016-04-22 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1.To elect the ten director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2017 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2.To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2016.
3.To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say-on-pay” vote).
|
| 2015-04-30 |
股东大会：
将于2015-06-04召开股东大会
会议内容 ▼▲
- 1. To elect the seven director nominees identified in the accompanying Proxy Statement to the Board of Directors of Amedisys, Inc. (the “Company”), each to serve a one-year term expiring at the latter of the 2016 Annual Meeting of the Company’s stockholders or upon his or her successor being elected and qualified.
2. To ratify the appointment of KPMG LLP as the Company’s independent registered public accountants for the fiscal year ending December 31, 2015.
3. To approve an amendment to the Company’s 2008 Omnibus Incentive Compensation Plan that would increase the number of shares of common stock authorized for issuance under the plan from 3,962,459 shares to 5,462,459 shares.
4. To approve, on an advisory (non-binding) basis, the compensation paid to the Company’s Named Executive Officers (“say-on-pay” vote).
|